Nicola Cascavilla
Overview
Explore the profile of Nicola Cascavilla including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
108
Citations
1769
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Barbui T, Vannucchi A, De Stefano V, Carobbio A, Ghirardi A, Carioli G, et al.
NEJM Evid
. 2024 Feb;
2(6):EVIDoa2200335.
PMID: 38320126
BACKGROUND: Whether phlebotomy alone can adequately maintain target hematocrit in patients with low-risk polycythemia vera (PV) remains elusive. METHODS: In a phase 2 open-label randomized trial, we compared ropeginterferon alfa-2b...
2.
Barbui T, Carobbio A, De Stefano V, Alvarez-Larran A, Ghirardi A, Carioli G, et al.
Ann Hematol
. 2023 Dec;
103(2):437-442.
PMID: 38060001
In patients with low-risk polycythemia vera, exposure to low-dose Ropeginterferon alfa-2b (Ropeg) 100 µg every 2 weeks for 2 years was more effective than the standard treatment of therapeutic phlebotomy...
3.
Mele G, Di Renzo N, Cascavilla N, Carella A, Guarini A, Mazza P, et al.
Leuk Lymphoma
. 2023 Jul;
64(10):1715-1718.
PMID: 37417467
No abstract available.
4.
Oliva E, Riva M, Niscola P, Santini V, Breccia M, Giai V, et al.
J Clin Oncol
. 2023 Jun;
41(28):4486-4496.
PMID: 37294914
Purpose: In myelodysplastic syndromes (MDS), severe thrombocytopenia is associated with poor prognosis. This multicenter trial presents the second-part long-term efficacy and safety results of eltrombopag in patients with low-risk MDS...
5.
Todisco E, Papayannidis C, Fracchiolla N, Petracci E, Zingaretti C, Vetro C, et al.
Cancer
. 2023 Jan;
129(7):992-1004.
PMID: 36692409
Background: Venetoclax in combination with hypomethylating agents (HMA) is revolutionizing the therapy of acute myeloid leukemia (AML). However, evidence on large sets of patients is lacking, especially in relapsed or...
6.
Efficace F, Gaidano G, Petrucci M, Niscola P, Cottone F, Codeluppi K, et al.
Lancet Healthy Longev
. 2022 Sep;
3(9):e628-e635.
PMID: 36102777
Background: The clinical management of patients with relapsed or refractory multiple myeloma is challenging and there is a paucity of tools to help clinicians make more informed decisions for the...
7.
Morabito F, Zamagni E, Conticello C, Pavone V, Palmieri S, Bringhen S, et al.
Front Oncol
. 2022 Aug;
12:890376.
PMID: 35924160
The present study aimed to develop two survival risk scores (RS) for overall survival (OS, SRS ) and progression-free survival (PFS, PRS ) in 919 relapsed/refractory multiple myeloma (RRMM) patients...
8.
Ferrero S, Grimaldi D, Genuardi E, Drandi D, Zaccaria G, Alessandria B, et al.
Blood
. 2022 Jun;
140(12):1378-1389.
PMID: 35737911
Minimal residual disease (MRD) analysis is a known predictive tool in mantle cell lymphoma (MCL). We describe MRD results from the Fondazione Italiana Linfomi phase 3 MCL0208 prospective clinical trial...
9.
Bruzzese A, Derudas D, Galli M, Martino E, Rocco S, Conticello C, et al.
Hematol Oncol
. 2022 May;
40(4):704-715.
PMID: 35608183
The combination of elotuzumab, lenalidomide, and dexamethasone (EloRd) enhanced the clinical benefit over Rd with a manageable toxicity profile in the ELOQUENT-2 trial, leading to its approval in relapsed/refractory multiple...
10.
DArgenio M, Tarantini G, Cascavilla N, Pavone E, Musto P, Mazza P, et al.
Cancers (Basel)
. 2022 Feb;
14(3).
PMID: 35159092
Decitabine, a DNA hypomethylating agent, was approved for use in adults with acute myeloid leukemia (AML) not eligible for standard chemotherapy and is now widely accepted as standard treatment. Although...